To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News | Institutional | Toxicology | Diagnosis and innovative treatment
A SIMOPRO project supported by SATT Paris-Saclay: in vivo validation of the efficacy of the DTR8 molecule, developed and patented at SIMOPRO (Department of Medicines and Technologies for Health) in collaboration with Inserm, as a treatment for glomerulonephritis rapidly progressive.
Daniel Gillet (SIMOPRO) and his team exploited the natural ability of diphtheria toxin to bind to the precursor of Heparin-binding Epidermal Growth Factor (Heparin Binding-Epidermal Growth Factor) to develop a very potent selective inhibitor of this growth factor: the DTR8 protein. In collaboration with Inserm's nephrologist Pierre-Louis Tharaux, DTR8 has shown efficacy in monkeys to treat rapidly progressive glomerulonephritis, a rare renal disease in which overexpression of the growth factor is directly involved. A patent covering Europe, the United States and Japan has been issued.Accompanied by the institute's Valo cell, and with the help of a first grant from the Rare Diseases Foundation, Daniel Gillet and his team set up a consortium of Inserm, SATT Paris-Saclay and an investor private, to fund in vivo proof of concept in a pig model representative of human pathology. With the maturation agreement just signed, the two-year program can now begin.At the end of the program, and in the event of a consolidated demonstration of the effectiveness of the therapeutic protein DTR8 against rapidly progressive glomerulonephritis, the objective will be to license the patent to a pharmaceutical manufacturer or to create a start-up.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.